Various studies revealed that DXL, a first-line drug for the treatment of many cancers, exhibited limited therapeutic efficacy partly due to activation of NF-κB (Kani et al., 2013; Shao et al., 2013; Pan et al., 2016). Here, NFKB1 is linked to cancer.